Zydus Cadila has got the US health regulator’s final approval for marketing amantadine tablets that are used for the treatment of Parkinson’s disease and select viral infections, in the American market.

Zydus Cadila’s group firm Cadila Healthcare has said in a BSE filing that the group has received the final approval from the US Food and Drug Administration (USFDA) to market Amantadine Hydrochloride Capsules USP, 100 mg.

Amantadine Hydrochloride are going to be produced at the groups formulations manufacturing facility at Pharma SEZ in Ahmedabad.

Read EquityPandit’s Nifty Pharma Outlook for this week